Chicago | Reuters — Zoetis Inc., the world’s largest animal-health company, plans to seek U.S. approval before the end of this year to sell its vaccine against a virus that has killed about 13 per ...

Zoetis offers the Suvaxyn MH-One vaccine. The vaccine is approved for use from seven days of age with a two-week onsent, which means piglets can be protected by three weeks of age, and the duration of ...

The Poulvac Maternavac 4 is an inactivated vaccine from Zoetis that helps protect chickens against four important diseases. This vaccine protects against standard and variant strains of infectious ...

They received Vaccine A, a competitor product, or Zoetis' Poulvac® Ovoline CVI. Each vaccine was administered at the higher recommended dose of 4,000 plaque-forming units or at a lower dose. At hatch, ...

Zoetis veterinarians initiated a study after a substantial increase in reovirus tenosynovitis occurred in several US broiler-producing regions during the winter of 2011-2012. Previous research has ...

Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $79.9 billion ...

Zoetis Inc. (ZTS), headquartered in Parsippany, New Jersey, is a global leader in animal health. It specializes in the development, manufacturing, and distribution of medicines, vaccines ...

The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 ...

Zoetis is a global leader in animal health, specializing in products for both companion animals and livestock. The company offers a diverse range of products, which includes medicines, vaccines ...